[go: up one dir, main page]

MX2017013154A - Conjugados anticuerpo-farmaco de sitio especifico. - Google Patents

Conjugados anticuerpo-farmaco de sitio especifico.

Info

Publication number
MX2017013154A
MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A
Authority
MX
Mexico
Prior art keywords
site
specific antibody
drug conjugates
amino acid
antibody
Prior art date
Application number
MX2017013154A
Other languages
English (en)
Inventor
Wilson Howard Philip
Hendrikus Cornelis Van Berkel Patricius
Original Assignee
Adc Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adc Therapeutics S A filed Critical Adc Therapeutics S A
Publication of MX2017013154A publication Critical patent/MX2017013154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen conjugados anticuerpo-fármaco de sitio específico, en particular conjugados que comprenden pirrolobenzodiazepinas (PBD) que tienen un grupo protector lábil en forma de un ligador. El sitio de conjugación, junto con la modificación del resto de anticuerpo, permite una mejora en la seguridad y la eficacia del ADC.
MX2017013154A 2015-04-15 2016-04-15 Conjugados anticuerpo-farmaco de sitio especifico. MX2017013154A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506393.6A GB201506393D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
PCT/EP2016/058371 WO2016166299A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (1)

Publication Number Publication Date
MX2017013154A true MX2017013154A (es) 2018-02-21

Family

ID=53333825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013154A MX2017013154A (es) 2015-04-15 2016-04-15 Conjugados anticuerpo-farmaco de sitio especifico.

Country Status (11)

Country Link
US (1) US20180125994A1 (es)
EP (1) EP3283118A1 (es)
JP (1) JP2018511628A (es)
KR (1) KR20170137115A (es)
CN (1) CN107683146A (es)
AU (1) AU2016249877A1 (es)
BR (1) BR112017022256A2 (es)
CA (1) CA2981920A1 (es)
GB (1) GB201506393D0 (es)
MX (1) MX2017013154A (es)
WO (1) WO2016166299A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62343B1 (sr) 2017-02-08 2021-10-29 Adc Therapeutics Sa Pirolobenzodiazepin-antitelo konjugati
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
US20200129638A1 (en) * 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-psma antibody-drug conjugate
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
CA3064681A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd25 adc
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3899048A1 (en) 2018-12-19 2021-10-27 ADC Therapeutics SA Pyrrolobenzodiazepine resistance
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
EP3938372B1 (en) 2019-03-15 2023-10-25 MedImmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
LT3946464T (lt) * 2019-03-29 2022-11-10 Medimmune Limited Junginiai ir jų konjugatai
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
CN116370651A (zh) * 2023-04-04 2023-07-04 上海愿智生物技术有限公司 一种抗psma抗体-药物缀合物及其制备方法和应用
WO2025145034A1 (en) * 2023-12-29 2025-07-03 T.O.A.D. Oncology Sa Anti-psma conjugates and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320403A1 (en) * 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
EP1817341A2 (en) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
EP2543730B1 (en) * 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP6014596B2 (ja) * 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
ES2680153T3 (es) * 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
NZ707486A (en) * 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP3038659A4 (en) * 2013-08-28 2017-07-26 AbbVie Stemcentrx LLC Engineered anti-dll3 conjugates and methods of use

Also Published As

Publication number Publication date
JP2018511628A (ja) 2018-04-26
US20180125994A1 (en) 2018-05-10
AU2016249877A1 (en) 2017-10-26
KR20170137115A (ko) 2017-12-12
CA2981920A1 (en) 2016-10-20
CN107683146A (zh) 2018-02-09
BR112017022256A2 (pt) 2018-07-31
GB201506393D0 (en) 2015-05-27
EP3283118A1 (en) 2018-02-21
WO2016166299A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2017013154A (es) Conjugados anticuerpo-farmaco de sitio especifico.
ZA201706745B (en) Site-specific antibody-drug conjugates
MX2017013171A (es) Conjugados anticuerpo-farmaco de sitio especifico.
ZA201805336B (en) Amanitin conjugates
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
ZA201903062B (en) Amanitin antibody conjugates
BR112016004242A2 (pt) métodos para conjugação sítio-específica de anticorpos e composições
ZA201903667B (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CY1123525T1 (el) Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
GEAP202214922A (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX395142B (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
IN2015DN02577A (es)
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2014134483A3 (en) Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
ZA202001747B (en) Psma-targeting amanitin conjugates
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
WO2018053552A3 (en) Isoquinolidinobenzodiazepines
IL272931A (en) Peptide conjugates, conjugation process and their uses
EP3775186A4 (en) ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND THEIR USES